Grünenthal Report 2022-2023

2022 was yet another fantastic year for Grünenthal. The company exceeded its financial and non-financial targets. Our revenue reached €1.7 billion, an increase of 13 percent compared to 2021. The adjusted EBIDTA reached €438 million, an increase of 18 percent over 2021, and has more than tripled since 2017. These record results were driven by increased demand for pain treatments and excellent sales performance across regions. Its financial success positions Grünenthal well to further invest in advancing the R&D pipeline, continuing the M&A strategy and growing the business in the United States.

To be updated